Healthcare Sales & Marketing Network News: antiplatelet therapy

Searching News Database: antiplatelet therapy

HSMN NewsFeed - 19 Mar 2025
Terumo Neuro Celebrates 15 Years of the WEB(TM) Device: A Game-Changing Innovation in Aneurysm Treatment
Devices Interventional Neurology

HSMN NewsFeed - 13 May 2022
Medtronic receives FDA approval for latest generation drug-eluting coronary stent system
Devices Interventional Cardiology FDA

HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2019
OrbusNeich(R) Announces Japan Approval for COMBO(R) Plus Coronary Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 18 Sep 2019
Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019
Devices Interventional Cardiology

HSMN NewsFeed - 6 Aug 2019
CeloNova Announces Appointment of New President and CEO
Devices Interventional Cardiology Personnel

HSMN NewsFeed - 4 Jun 2019
GORE(R) CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects
Devices Interventional Cardiology FDA

HSMN NewsFeed - 27 Aug 2018
Janssen Announces Results from MARINER and COMMANDER HF Studies
Biopharmaceuticals Cardiology

HSMN NewsFeed - 3 Apr 2018
FDA Approves GORE(R) CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke
Devices Interventional Cardiology FDA

HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Mar 2017
CeloNova Biosciences Receives FDA Approval of COBRA PzF(TM) Stent System
Devices Interventional Cardiology FDA

HSMN NewsFeed - 12 Feb 2016
Sequent Medical Announces Initiation Of Study For The WEB Aneurysm Embolization System In Ruptured Aneurysms
Devices Neurosurgery Interventional Radiology

HSMN NewsFeed - 10 Dec 2015
Antonio Colombo, MD appointed Member of the Scientific Advisory Council of Miracor Medical Systems
Devices Interventional Cardiology Personnel

HSMN NewsFeed - 16 Sep 2014
First-In-Man Study of the COBRA PzF(TM) Coronary Stent Shows Promising Results Highlighted by Short, 30-Day Dual-Antiplatelet Therapy and Low, 3% TLR Rate
Devices Interventional Cardiology

HSMN NewsFeed - 16 Jul 2014
First Patient Enrolment in MASCOT Registry Represents Major Milestone for COMBO(TM) Dual Therapy Stent and OrbusNeich's Clinical Programme
Devices Interventional Cardiology

HSMN NewsFeed - 23 May 2014
OrbusNeich Releases Long-term Data for World's First and Only Dual Therapy Stent
Devices Interventional Cardiology

HSMN NewsFeed - 21 May 2014
Boston Scientific Reports Strong Performance Data For SYNERGY(TM) Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 23 Dec 2013
European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 17 Oct 2013
Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013
Devices Interventional Cardiology

HSMN NewsFeed - 30 Aug 2013
ITC Acquires Accumetrics to Form Leading POC Cardiovascular Diagnostics Business
Diagnostics Cardiology Mergers & Acquisitions

HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2013
OrbusNeich Launches World's First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents
Devices Interventional Cardiology Product Launch

HSMN NewsFeed - 22 May 2013
Boston Scientific Promus PREMIER(TM) and SYNERGY(TM) Drug-Eluting Stent Systems Provide Exceptional Safety and Efficacy Data
Devices Interventional Cardiology

HSMN NewsFeed - 22 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology

HSMN NewsFeed - 20 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology

HSMN NewsFeed - 17 May 2013
Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
Devices Interventional Cardiology

HSMN NewsFeed - 21 Jan 2013
OrbusNeich's COMBO Dual Therapy Stent(TM) to Be Featured During AsiaPCR/SingLIVE 2013 Symposium
Devices Interventional Cardiology

HSMN NewsFeed - 30 Nov 2012
First Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY(TM) Coronary Stent System Featuring a Bioabsorbable Polymer Coating
Devices Interventional Cardiology

HSMN NewsFeed - 14 Nov 2012
Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents
Devices Interventional Cardiology

HSMN NewsFeed - 31 Oct 2012
Boston Scientific Receives CE Mark Approval for the SYNERGY(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 8 Aug 2012
Cardionovum(R) Expects to Launch Next-Generation Product: Drug-Eluting Coronary Stent System, “PROLIMUS Biograde”
Devices Interventional Cardiology

HSMN NewsFeed - 17 May 2012
Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent(TM) Compared to the TAXUS(R) Stent Shown in Two Clinical Trial Subgroup Analyses
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2012
One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY(TM) Stent Versus PROMUS Element(TM) Platinum Chromium Stent
Devices Interventional Cardiology

HSMN NewsFeed - 11 May 2012
Study of First-in-Class WATCHMAN(R) Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
Devices Interventional Cardiology

HSMN NewsFeed - 10 May 2012
Boston Scientific Announces Schedule For EuroPCR 2012
Devices Interventional Cardiology

HSMN NewsFeed - 22 Mar 2012
OrbusNeich's Genous(TM) Technology Effectively Promotes Endothelialization and Reduces Thrombogenicity
Devices Interventional Cardiology

HSMN NewsFeed - 5 Jan 2012
OrbusNeich's Genous(TM) Stent Achieves Good, Comparable Clinical Outcomes in Patients Discontinuing Dual Antiplatelet Therapy at 30 Days and at Six Months
Devices Interventional Cardiology

HSMN NewsFeed - 5 Dec 2011
Data Published in EuroIntervention Indicate that OrbusNeich's Genous(TM) Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy
Devices Interventional Cardiology

HSMN NewsFeed - 18 Jul 2011
OrbusNeich's Genous Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
Devices Interventional Cardiology

HSMN NewsFeed - 18 May 2011
Medtronic Resolute(R) Drug-Eluting Stent Offers Strong Performance in Diabetic Patients with Heart Disease
Devices Interventional Cardiology

HSMN NewsFeed - 11 May 2011
Accumetrics Signs National Distribution Agreement with Cardinal Health
Diagnostics Personalized Medicine Cardiology Distribution

HSMN NewsFeed - 23 Mar 2011
Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeich's Genous Stent in Diabetic Patients
Devices Interventional Cardiology

HSMN NewsFeed - 22 Feb 2011
Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous Stent
Devices Interventional Cardiology

HSMN NewsFeed - 10 Jan 2011
Safety and Efficacy of OrbusNeich's Genous Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
Devices Interventional Cardiology

HSMN NewsFeed - 2 Dec 2010
OrbusNeich's Genous Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
Devices Interventional Cardiology

HSMN NewsFeed - 16 Nov 2010
GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI
Diagnostics Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 24 Sep 2010
Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Devices Interventional Cardiology

HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Jun 2010
Data Show OrbusNeich's Genous Bio-engineered R stent is Safe and Effective in Combination with Drug-Eluting Balloon
Devices Interventional Cardiology

HSMN NewsFeed - 26 May 2010
Data Presented at EuroPCR 2010 Demonstrate Effectiveness of OrbusNeich's Genous Bio-engineered R stent in Diabetic Patients
Devices Interventional Cardiology

HSMN NewsFeed - 26 May 2010
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
Devices Interventional Cardiology

HSMN NewsFeed - 25 May 2010
NEVO Sirolimus-eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Devices Interventional Cardiology

HSMN NewsFeed - 20 Apr 2010
OrbusNeich Announces Full Availability of Genous(TM) Bio-engineered Cobalt Chromium Stent Following CE Mark Approval
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 15 Mar 2010
Inadequate Response to Clopidogrel Leads to Higher Incidence of Major Adverse Cardiac Events in Patients Who have Undergone PCI
Biopharmaceuticals Diagnostics Cardiology

HSMN NewsFeed - 11 Feb 2010
OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
Devices Interventional Cardiology

HSMN NewsFeed - 1 Feb 2010
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI
Devices Interventional Cardiology

HSMN NewsFeed - 4 Jan 2010
Boston Scientific Announces Enrollment of First Patient in Post-Approval Study for TAXUS Liberte Stent
Devices Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 1 Dec 2009
OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 24 Sep 2009
Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Sep 2009
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI
Devices Interventional Cardiology

HSMN NewsFeed - 22 Sep 2009
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Devices Interventional Cardiology

HSMN NewsFeed - 31 Aug 2009
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology

HSMN NewsFeed - 31 Aug 2009
sanofi-aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 May 2009
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 4 May 2009
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
Biopharmaceuticals

HSMN NewsFeed - 22 Apr 2009
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
Devices Interventional Cardiology

HSMN NewsFeed - 8 Apr 2009
World-First Launch of New Heart Drug
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 16 Mar 2009
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO Sirolimus-Eluting Coronary Stent to the XIENCE Stent
Devices Interventional Cardiology

HSMN NewsFeed - 12 Mar 2009
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 9 Mar 2009
Merck and Schering-Plough to Merge
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Feb 2009
Medtronic Completes Enrollment in Global Head-to-Head Stent-Safety Study
Devices Interventional Cardiology

HSMN NewsFeed - 27 Jan 2009
SurModics and Nexeon MedSystems to Collaborate on Development of Novel Stent System for Renal Artery Disease
Devices Interventional

HSMN NewsFeed - 14 Oct 2008
Endeavor(R) Vs. Taxus(R): Medtronic's Drug-Eluting Coronary Stent Linked to Fewer Heart Attacks at Two Years Post Implant
Devices Interventional Cardiology

HSMN NewsFeed - 13 Oct 2008
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Devices Interventional Cardiology

HSMN NewsFeed - 7 Jul 2008
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 28 May 2008
OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 15 May 2008
International Endeavor Registry Reports Safety and Performance of Medtronic Drug-Eluting Stent in Diverse Patient Population
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2008
Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2008
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
Neurology

HSMN NewsFeed - 13 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Devices Interventional Cardiology

HSMN NewsFeed - 31 Mar 2008
Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Biopharmaceuticals Cardiology

HSMN NewsFeed - 30 Mar 2008
Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
Devices Interventional Cardiology

HSMN NewsFeed - 29 Mar 2008
Endeavor(R) Stent Safety Profile Affirmed in Long-Term Experience
Devices Interventional Cardiology

HSMN NewsFeed - 29 Mar 2008
Study Finds Repeated Episodes of Stent Thrombosis Common
Devices Interventional Cardiology

HSMN NewsFeed - 26 Mar 2008
Medtronic's New Endeavor(R) Zotarolimus-Eluting Stent Approved for Patients with Coronary Artery Disease in Canada
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 1 Feb 2008
Medtronic Receives FDA Approval for Endeavor(R) Zotarolimus-Eluting Coronary Stent System
Devices Interventional Cardiology FDA

HSMN NewsFeed - 21 Jan 2008
Super-Thin Drug-Free Coating 'Hides' Stent as It Unblocks Heart Arteries
Devices Interventional Cardiology

HSMN NewsFeed - 10 Jan 2008
OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
Devices Interventional Cardiology

HSMN NewsFeed - 9 Jan 2008
ThromboVision's T-Guide(R) Clinical Trials Under Way
Devices Monitoring Cardiology

HSMN NewsFeed - 13 Dec 2007
PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 29 Nov 2007
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 27 Nov 2007
Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE(TM) V Drug Eluting Stent to FDA Advisory Committee on Nov. 29
Devices Interventional Cardiology

HSMN NewsFeed - 4 Nov 2007
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 22 Oct 2007
Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
Devices Interventional Cardiology

HSMN NewsFeed - 22 Oct 2007
Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 Oct 2007
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 13 Sep 2007
ThromboVision Closes $4 Million Series A Financing
Diagnostics Venture Capital

HSMN NewsFeed - 5 Sep 2007
REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
Cardiology

HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology

HSMN NewsFeed - 3 Sep 2007
Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 7 Aug 2007
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
Biopharmaceuticals Cardiology

HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 May 2007
Efficacy of OrbusNeich's Genous(TM) Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 22 May 2007
ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 18 May 2007
Medtronic Announces Schedule of Activities at EuroPCR
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2007
Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Devices Interventional Cardiology

HSMN NewsFeed - 24 Mar 2007
Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

Return to NewsFeed

Additional items found! 19

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 19 additional stories matching:
antiplatelet therapy
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.